These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23904552)

  • 1. Serum lipids as biomarkers for therapeutic monitoring of latent tuberculosis infection.
    Albanna AS; Bachmann K; White D; Valiquette C; Menzies D
    Eur Respir J; 2013 Aug; 42(2):547-50. PubMed ID: 23904552
    [No Abstract]   [Full Text] [Related]  

  • 2. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intensive chemotherapy of pulmonary tuberculosis].
    Shesterina MV; Gavrilenko VS; Tarasova EF; Sokolova GV; Tregubov IuG
    Probl Tuberk; 1980 Jul; (7):20-22. PubMed ID: 6997865
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K; Aspler A; Menzies D; Schwartzman K
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent Mycobacterium tuberculosis infection.
    Getahun H; Matteelli A; Chaisson RE; Raviglione M
    N Engl J Med; 2015 May; 372(22):2127-35. PubMed ID: 26017823
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
    Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
    [No Abstract]   [Full Text] [Related]  

  • 9. Question 1: what are the options for treating latent TB infection in children?
    Gwee A; Coghlan B; Curtis N
    Arch Dis Child; 2013 Jun; 98(6):468-74. PubMed ID: 23661667
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
    Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
    Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immigrants with latent tuberculosis infection: a moving target?
    Chee CB
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):287. PubMed ID: 23407217
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hepatic tuberculosis: a case with pseudotumours form].
    Sève P; Boibieux A; Biron F; Bouhour D; Rode A; Bancel B; Chidiac C; Peyramond D
    Ann Med Interne (Paris); 1998 Oct; 149(6):386-8. PubMed ID: 9853049
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous tuberculosis: efficient therapeutic response in a case with multiple lesions.
    Chinchilla D; Martorano A; Rodriguez E; Villanueva C
    Cutis; 1999 Jul; 64(1):49-52. PubMed ID: 10431674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
    Khodashova ML; Iuditskiĭ MV; Semenova OV
    Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of latent tuberculosis infection.
    Lepage P
    N Engl J Med; 2003 Mar; 348(13):1292-3; author reply 1292-3. PubMed ID: 12661577
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of newly diagnosed patients with infiltrative and disseminated pulmonary tuberculosis].
    Ursov IG; Krasnov VA; B1tashova VA; Kudelia OA; Volkova ZhA; Gromyko NI; Borovinskaia TA
    Probl Tuberk; 1998; (4):21-2. PubMed ID: 9771031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of latent tuberculosis infection].
    Fraisse P;
    Rev Mal Respir; 2012 Apr; 29(4):579-600. PubMed ID: 22542415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.